HIF‐1α and CA‐IX as predictors of locoregional control for determining the optimal treatment modality for early‐stage laryngeal carcinoma. Issue 4 (9th April 2014)

• Record Type: Journal Article
• Authors: Kwon, Oh Jin; Park, Jung Je; Ko, Gyung Hyuck; Seo, Ji Hyun; Jeong, Bae‐Kwon; Kang, Ki Mun; Woo, Seung Hoon; Kim, Jin Pyeong; Hwa, Jeong Seok; Carey, Thomas E.
• Is Part Of: Head & neck. Volume 37:Issue 4(2015:Apr.)
• Page Start: 505
• Page End: 510
• Publication Date: 2014-04-09
• Subjects: laryngeal carcinoma -- radiotherapy -- hypoxia‐inducible factor‐1α -- carbonic anhydrase IX -- glucose transporter‐1; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.23620
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: The purpose of this study was to examine the predictive value of hypoxia‐inducible factor (HIF)−1α, carbonic anhydrase (CA)‐IX, glucose transporter (GLUT)−1, cyclooxygenase (COX)−2, Ki‐67, and erythropoietin receptor (EPOR) as immunohistochemical markers for determining the optimal treatment modality for early stage laryngeal carcinoma. Methods: Tissue samples from 42 early stage laryngeal carcinomas treated with radiotherapy alone were analyzed immunohistochemically for the expression of 6 markers. The Kaplan–Meier method, univariate and multivariate analyses, and the Cox proportional hazards model were used to analyze the associations between patient and tumor characteristics and immunohistochemical results, and locoregional control. Results: Increased expression of HIF‐1α and CA‐IX was significantly correlated with residual tumor; no correlations were observed for the other immunohistochemical markers. Conclusion: High levels of HIF‐1α or CA‐IX expression were significantly correlated with residual tumor after radiotherapy for early stage laryngeal carcinomas. Alternative treatment modalities to primary radiotherapy should be considered for early stage laryngeal carcinomas showing high HIF‐1α or CA‐IX expression. © 2014 Wiley Periodicals, Inc. Head Neck 37 : 505–510, 2015